FREE subscriptions for doctors and students... click here
You have 3 more open access pages.
Antidepressant drugs modify the levels of monoaminergic neurotransmitters in
the brain. The raphe nucleus in the brain stem contains the cell bodies of these
serotonergic and noradrenergic neurones which innervate wide areas of the brain.
Synaptic levels of monoamines, particularly serotonin, are thought to be decreased
in depression.
The main classes of antidepressants are:
- tricyclic
antidepressants
- serotonin-selective reuptake inhibitors
- noradrenergic
and and specific serotonergic antidepressants
Monoamine oxidase A
inhibitors are no longer in routine use.
Lithium is used in bipolar affective
disorder and in cases of resistant depression.
Antidepressant drugs in mild depression:
- randomised controlled trial (RCT) evidence indicates that for many patients
there is little clinically important difference between antidepressants and
placebo, and the placebo response is greatest in mild depression
- antidepressants are not recommended for the initial treatment of mild depression,
because the risk-benefit ratio is poor
- mild or persistent subthreshold depression
- do not use antidepressants routinely to treat persistent subthreshold
depressive symptoms or mild depression because the risk–benefit ratio
is poor, but consider them for people with:
- a past history of moderate or severe depression or
- initial presentation of subthreshold depressive symptoms that have
been present for a long period (typically at least 2 years) or
- subthreshold depressive symptoms or mild depression that persist(s)
after other interventions
- do not use antidepressants routinely to treat subthreshold depressive
symptoms or mild depression in patients with a chronic physical health problem
(because the risk–benefit ratio is poor), but consider them for patients
with:
- a past history of moderate or severe depression or
- mild depression that complicates the care of the physical health problem
or
- initial presentation of subthreshold depressive symptoms that have
been present for a long period (typically at least 2 years) or
- subthreshold depressive symptoms or mild depression that persist(s)
after other interventions
Antidepressant drugs in moderate or severe depression
- in moderate to severe depression there is more evidence for the effectiveness
of antidepressant medication than in milder depression
- for routine care, a selective serotonin reuptake inhibitor is the first
choice drug - because SSRIs are as effective as tricyclic antidepressants
and are less likely to be discontinued because of side effects
- careful monitoring of symptoms, side effects and suicide risk (particularly
in those aged under 30) should be routinely undertaken, especially when initiating
antidepressant medication
- moderate or severe depression
- for people with moderate or severe depression, provide a combination
of antidepressant medication and a high-intensity psychological intervention
(CBT or interpersonal therapy [IPT])
- when an antidepressant is to be prescribed for a patient with depression
and a chronic physical health problem, take into account the following:
- the presence of additional physical health disorders
- the side effects of antidepressants, which may impact on the underlying
physical disease (in particular, SSRIs may result in or exacerbate hyponatraemia,
especially in older people)
- that there is no evidence as yet supporting the use of specific antidepressants
for patients with particular chronic physical health problems
- interactions with other medications
For more detailed guidance then refer to full updated NICE guideline (2).
Reference:
- NICE (April 2007). Management
of depression in primary and secondary care.
- NICE (April 2018). Depression
- Anderson IM et al (2000). Evidence-based guidelines for treating depressive
disorders with antidepressants: a revision of the 1993 British Association
for Psychopharmacology guidelines. J Psychopharmacol;14: 3-20.
Last edited 08/2018 and last reviewed 02/2020
Links: